Pfizer and BioNTech to submit to FDA today for emergency authorization for their coronavirus vaccine. It is known that a vaccine called BNT162b2 will be available in the United States by mid to late December. This unexpected news, which can be found on the front page of any newspaper and magazine 4 free, came at the height of the second wave of the coronavirus pandemic, and if the data are confirmed, then the victory over Covid-19 is not far off.
The number of people infected with the new coronavirus infection in the world has exceeded 50 million. Given the difficult epidemiological situation in Europe, the United States, and other countries, the news that Pfizer and BioNTech to submit to FDA today for emergency authorization for their coronavirus vaccine looks like a hope of salvation, as many scientists and doctors openly declare.
At the same time, Pfizer and BioNTech began the application process with medical regulators in the UK, Australia, Canada, Japan, and other countries, as well as the European Medicines Agency (EMA).
What did the new vaccine tests show?
Long before the news headlines “Pfizer and BioNTech to submit to FDA today for emergency authorization for their coronavirus vaccine” appeared, experts around the world had questions about the effectiveness of this vaccine.
According to the developers and the latest business news, about 43.5 thousand people took part in the tests of the BNT162b2 vaccine, about half of whom received a placebo.
At the same time, of the 170 cases of COVID-19 among the participants, only 8 are among those who did not receive a placebo. As a result of studies, a 95% efficacy of the drug has been proven. Side effects have not yet been noticed, but experts do not exclude that they may appear in the future, the TV channel reports.
Are there any alternatives to BNT162b2?
The new vaccine is not the only one in the world. The American company Moderna, the Swedish-British pharmaceutical concern AstraZeneca, the companies Sanofi, Sinovac, and Johnson & Johnson also achieved some success in the development of a vaccine against COVID-19.
In China and Russia, vaccinations are already being carried out with drugs developed in national laboratories, however, there is no conclusive evidence of their effectiveness. The lack of transparency regarding preclinical or clinical trial results, not to mention transparency regarding due process, continues to be a concern of medical professionals around the world.
Let’s hope the new coronavirus vaccine from Pfizer and BioNTech puts an end to the pandemic!